FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418783983> ?p ?o ?g. }

• W2418783983 abstract "There is a lack of information about the sensitivity, specificity and costs new diagnostic tests should have to improve early diagnosis of rheumatoid arthritis (RA). Our objective was to explore the early cost-effectiveness of various new diagnostic test strategies in the workup of patients with inflammatory arthritis (IA) at risk of having RA. A decision tree followed by a patient-level state transition model, using data from published literature, cohorts and trials, was used to evaluate diagnostic test strategies. Alternative tests were assessed as add-on to or replacement of the ACR/EULAR 2010 RA classification criteria for all patients and for intermediate-risk patients. Tests included B-cell gene expression (sensitivity 0.60, specificity 0.90, costs €150), MRI (sensitivity 0.90, specificity 0.60, costs €756), IL-6 serum level (sensitivity 0.70, specificity 0.53, costs €50) and genetic assay (sensitivity 0.40, specificity 0.85, costs €750). Patients with IA at risk of RA were followed for 5 years using a societal perspective. Guideline treatment was assumed using tight controlled treatment based on DAS28; if patients had a DAS28 >3.2 at 12 months or later patients could be eligible for starting biological drugs. The outcome was expressed in incremental cost-effectiveness ratios (€2014 per quality-adjusted life year (QALY) gained) and headroom. The B-cell test was the least expensive strategy when used as an add-on and as replacement in intermediate-risk patients, making it the dominant strategy, as it has better health outcomes and lower costs. As add-on for all patients, the B-cell test was also the most cost-effective test strategy. When using a willingness-to-pay threshold of €20,000 per QALY gained, the IL-6 and MRI strategies were not cost-effective, except as replacement. A genetic assay was not cost-effective in any strategy. Probabilistic sensitivity analysis revealed that the B-cell test was consistently superior in all strategies. When performing univariate sensitivity analysis for intermediate-risk patients, specificity and DAS28 in the B-cell add-on strategy, and DAS28 and sensitivity in the MRI add-on strategy had the largest impact on the cost-effectiveness. This early cost-effectiveness analysis indicated that new tests to diagnose RA are most likely to be cost-effective when the tests are used as an add-on in intermediate-risk patients, and have high specificity, and the test costs should not be higher than €200–€300." @default.
• W2418783983 created "2016-06-24" @default.
• W2418783983 creator A5010272673 @default.
• W2418783983 creator A5018580363 @default.
• W2418783983 creator A5023709885 @default.
• W2418783983 creator A5075713646 @default.
• W2418783983 creator A5090139465 @default.
• W2418783983 date "2016-06-10" @default.
• W2418783983 modified "2023-10-07" @default.
• W2418783983 title "A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis" @default.
• W2418783983 cites W1978091951 @default.
• W2418783983 cites W1984000202 @default.
• W2418783983 cites W1992681476 @default.
• W2418783983 cites W1993162189 @default.
• W2418783983 cites W1994932727 @default.
• W2418783983 cites W1997445449 @default.
• W2418783983 cites W2013164163 @default.
• W2418783983 cites W2023812288 @default.
• W2418783983 cites W2031154201 @default.
• W2418783983 cites W2031559585 @default.
• W2418783983 cites W2031972477 @default.
• W2418783983 cites W2036902803 @default.
• W2418783983 cites W2044804318 @default.
• W2418783983 cites W2063217417 @default.
• W2418783983 cites W207815171 @default.
• W2418783983 cites W2083673654 @default.
• W2418783983 cites W2093425496 @default.
• W2418783983 cites W2098564698 @default.
• W2418783983 cites W2099561206 @default.
• W2418783983 cites W2099578682 @default.
• W2418783983 cites W2099699365 @default.
• W2418783983 cites W2103310388 @default.
• W2418783983 cites W2104669609 @default.
• W2418783983 cites W2110177517 @default.
• W2418783983 cites W2110363668 @default.
• W2418783983 cites W2113409788 @default.
• W2418783983 cites W2114229314 @default.
• W2418783983 cites W2119723487 @default.
• W2418783983 cites W2119945666 @default.
• W2418783983 cites W2138657325 @default.
• W2418783983 cites W2139439610 @default.
• W2418783983 cites W2141161528 @default.
• W2418783983 cites W2142796764 @default.
• W2418783983 cites W2146062321 @default.
• W2418783983 cites W2148357532 @default.
• W2418783983 cites W2162254515 @default.
• W2418783983 cites W2168239913 @default.
• W2418783983 cites W2168368423 @default.
• W2418783983 cites W2206432491 @default.
• W2418783983 cites W2325854671 @default.
• W2418783983 cites W2331760140 @default.
• W2418783983 doi "https://doi.org/10.1186/s13075-016-1020-3" @default.
• W2418783983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4902954" @default.
• W2418783983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27287375" @default.
• W2418783983 hasPublicationYear "2016" @default.
• W2418783983 type Work @default.
• W2418783983 sameAs 2418783983 @default.
• W2418783983 citedByCount "13" @default.
• W2418783983 countsByYear W24187839832017 @default.
• W2418783983 countsByYear W24187839832019 @default.
• W2418783983 countsByYear W24187839832020 @default.
• W2418783983 countsByYear W24187839832021 @default.
• W2418783983 countsByYear W24187839832022 @default.
• W2418783983 countsByYear W24187839832023 @default.
• W2418783983 crossrefType "journal-article" @default.
• W2418783983 hasAuthorship W2418783983A5010272673 @default.
• W2418783983 hasAuthorship W2418783983A5018580363 @default.
• W2418783983 hasAuthorship W2418783983A5023709885 @default.
• W2418783983 hasAuthorship W2418783983A5075713646 @default.
• W2418783983 hasAuthorship W2418783983A5090139465 @default.
• W2418783983 hasBestOaLocation W24187839831 @default.
• W2418783983 hasConcept C126322002 @default.
• W2418783983 hasConcept C142724271 @default.
• W2418783983 hasConcept C177713679 @default.
• W2418783983 hasConcept C1862650 @default.
• W2418783983 hasConcept C198451711 @default.
• W2418783983 hasConcept C2777077863 @default.
• W2418783983 hasConcept C2777575956 @default.
• W2418783983 hasConcept C2780182762 @default.
• W2418783983 hasConcept C71924100 @default.
• W2418783983 hasConceptScore W2418783983C126322002 @default.
• W2418783983 hasConceptScore W2418783983C142724271 @default.
• W2418783983 hasConceptScore W2418783983C177713679 @default.
• W2418783983 hasConceptScore W2418783983C1862650 @default.
• W2418783983 hasConceptScore W2418783983C198451711 @default.
• W2418783983 hasConceptScore W2418783983C2777077863 @default.
• W2418783983 hasConceptScore W2418783983C2777575956 @default.
• W2418783983 hasConceptScore W2418783983C2780182762 @default.
• W2418783983 hasConceptScore W2418783983C71924100 @default.
• W2418783983 hasFunder F4320323596 @default.
• W2418783983 hasFunder F4320323768 @default.
• W2418783983 hasIssue "1" @default.
• W2418783983 hasLocation W24187839831 @default.
• W2418783983 hasLocation W24187839832 @default.
• W2418783983 hasLocation W24187839833 @default.
• W2418783983 hasLocation W24187839834 @default.
• W2418783983 hasLocation W24187839835 @default.
• W2418783983 hasLocation W24187839836 @default.
• W2418783983 hasLocation W24187839837 @default.
• W2418783983 hasLocation W24187839838 @default.

• next